Lyn Thyer Re Arrested 16.12.19 - Video Youtube
Mail: All, nothing further from Scott Tips on NHF yesterday evening but here are Ramola, Neelu and David William to be going on with anyway (thanks guys, great discussion, even if it doesn’t throw much further light on what happened in Paris yesterday nor why Lynda has been sent back to prison? but we all may have our own idea on that..
The Authority of The Courts & Crown Are Now Being Challenged By The People.
Latest: Victory For Lyn Thyer Release: November 29, 2019
A Parisian court, ruled over by a tough but fair judge, has ordered the French government today to release biochemist Lynda Thyer from prison, where she has been held since being kidnapped from England last August on a completely illegal European Arrest Warrant (EAW). The National Health Federation (NHF) retained the French criminal-law specialist attorney who won the court hearing today by arguing strenuously that the French government was acting illegally under European Union law, especially where the European Court of Justice is challenging the validity of the EAW because in France it is issued by a prosecutor and the prosecutor is not an independent judge according to required European standards.
Ms. Thyer will be released on Sunday, December 8, 2019, unless the government appeals and wins in the Court of Appeals. NHF’s legal team, which has won previous high-profile cases in France, has every intention of winning and forcing the government to free the innocent Lynda Thyer. This could turn out to be a landmark case since its outcome could affect every other EAW issued by French prosecutors.
Unlawful Extradition to France Lyn Thyer
AV10 - Ian Crane.
There have been over 160 clinical studies conducted on GcMAF and related immunotherapy areas. These are available for public viewing at the US National Library Medicine website (PUBMED) here. The different conditions and health issues which these studies have covered are listed below. We make no direct health claims about the use of GcMAFplus products. Our primary goal is to supply the highest quality clinical-grade products containing synthetic GcMAF bioidentical to what is produced within the body of a healthy individual.
Kidney CKD, Liver Disease: severe cirrhosis
Multiple Sclerosis, MS
Inflammation, viral and bacterial infections
A summary of clinical trials conducted on GcMAF
Actin scavenger - vitamin D binding protein also binds to actins. These are long filaments that can cause blood clots and lack of actin scavenging can lead to blood clots. First aid to burns shows a much-enhanced healing time.
Nagalase - an enzyme made by cancers and some pathogens which damages the glycoprotein at the exact place where GcMAF is made, meaning that the immune system remains compromised. A Nagalase test is a sensitive marker of cancer, giving a warning long before it is visible on a scan.
Autism - although there no known causes for autism, this group have a higher than normal level of Nagalase indicating a compromised and inactive immune system.
CFS - as with autism, no known cause, but immune compromised.
Lyme disease - often caused by multiple infections, long term antibiotic use is the usual method, but a long term immune support allowing the body to build immunity is an alternative
Auto immune conditions - the protein is an immune system mediator and has been shown to turn off (by apoptosis) macrophages when no longer needed at the site of an infection
Bone health - osteoclasts, the bone equivalent of macrophages, help with the adsorption and reforming of bone. May help speed healing times in fractures, hip replacements etc. and may be beneficial in osteoporosis.
Cancer - the protein not only activates macrophages, it has also been demonstrated to prevent the formation of blood vessels to the cancer (anti-angiogenesis), and prevent metastatic events. 100ng per week was shown to prevent the evolution of secondary cancers following allopathic treatments (this group still had evidence of disease from high Nagalase levels but nothing was visible on regular tests). 4ng per kg body weight per day was shown to start reducing solid tumours (for an average weight female, approx. 300ng per day, or three applications of frankincense cream per day)
Immune regulation - as well as being a mediator of macrophages, a paper exploring the endocannabinoid system and GcMAF showed that it down regulated overactive macrophages.
Nitric oxide production - GcMA activated macrophages produce large quantities of nitric oxide, improving blood flow and further supporting immunity. Regulates healthy blood pressure
Stroke and brain injury repair - Activation of M2 macrophages by GcMAF a week after a stroke may be associated with brain repair.
Vitamin D transport - because the vitamin D transport system is being improved, the levels of vitamin D can be used up quickly, so it is worth keeping an eye on levels.
Almost anything - if an improved immune system can help with it, then GcMA might improve the immune system to help with it.
Who can use It?
Anyone! If the immune system was working as it should, GcMAF would be made in the body and the immune system would be working. Do not stop or change any prescribed medication or treatment. If a healthy person can take the prescribed treatment, someone using GcMAFplus can. The only things to consider are if the medication is designed to suppress the immune system, it might counter the effects of GcMAF.
What diet or supplements are needed?
Vitamin D3 combined with K2 is often used. Because this is part of the vitamin D transport system, vitamin D levels can drop since it makes the vitamin more available for use, so it is worth keeping an eye on levels. If there is adequate sunshine exposure, supplementation may not be necessary.
A diet high in healthy, organic fatty acids can be beneficial - vitamin D is a fat based molecule and the vitamin D binding protein also binds to fatty acids to become the active form.
There have been no reported negative side effects associated with taking GcMAF; either by our own customers or those who have participated in trials with other organisations.
GC MAF Update 9000 Patients 30.5.19
CURING PEOPLE DOESNT PAY-Goldman Sachs
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.
“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
COMMON LAW COURT UPDATE